REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

17/12/2020 16:00

RNS Number : 0639J
  
AstraZeneca PLC
  
17 December 2020
  
 

17 December 2020 16:00 GMT
 
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
 
AstraZeneca PLC (the Company) announces that, on 16 December 2020, it was notified of transactions in the Company's Ordinary Shares of $0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities (PDMRs) of the Company as set out below.  Two ADSs are equivalent to one Ordinary Share. 
 



PDMR


Position


Nature of the transaction


Quantity


Price




Michel Demaré


Non-Executive Director


Purchase of Ordinary Shares 


1,300


GB£76.80




Euan Ashley


Non-Executive Director


Purchase of ADSs


700


US$51.52



 
 
 
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
 



1 
 


Details of the person discharging managerial responsibilities / person closely associated 
 




a) 
 


Name 
 
 


Michel Demaré




2 
 


Reason for the notification 
 




a) 
 


Position/status 
 
 


Non-Executive Director




b) 
 


Initial notification /Amendment 
 
 


Initial notification




3 
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
 




a) 
 


Name 
 
 


AstraZeneca PLC




b) 
 


LEI 
 
 


PY6ZZQWO2IZFZC3IOL08




4 
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
 
 




a) 
 


Description of the financial instrument, type of instrument 
 
Identification code 
 
 


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b) 
 


Nature of the transaction 
 
 


Purchase of AstraZeneca PLC Ordinary Shares




c) 
 


Price(s) and volume(s) 
 
 


 



Price(s)
 


Volume(s)




GB£76.80


1,300



 
 




d) 
 


Aggregated information 
 
 
- Aggregated volume 
 
 
- Price 
 
 


Not applicable - single transaction
 




e) 
 


Date of the transaction 
 
 


16 December 2020




f) 
 


Place of the transaction 
 
 


XLON



 
 



1 
 


Details of the person discharging managerial responsibilities / person closely associated 
 




a) 
 


Name 
 
 


Euan Ashley




2 
 


Reason for the notification 
 




a) 
 


Position/status 
 
 


Non-Executive Director




b) 
 


Initial notification /Amendment 
 
 


Initial notification




3 
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
 




a) 
 


Name 
 
 


AstraZeneca PLC




b) 
 


LEI 
 
 


PY6ZZQWO2IZFZC3IOL08




4 
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
 
 




a) 
 


Description of the financial instrument, type of instrument 
 
Identification code 
 
 


AstraZeneca PLC American Depositary Shares
 
 
CUSIP: 046353108 




b) 
 


Nature of the transaction 
 
 


Purchase of AstraZeneca PLC American Depositary Shares




c) 
 


Price(s) and volume(s) 
 
 


 



Price(s)
 


Volume(s)




US$51.52


700



 
 




d) 
 


Aggregated information 
 
 
- Aggregated volume 
 
 
- Price 
 
 


Not applicable - single transaction
 
 
 
 




e) 
 


Date of the transaction 
 
 


16 December 2020




f) 
 


Place of the transaction 
 
 


XNAS



 
 
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
Adrian Kemp

Company Secretary
AstraZeneca PLC
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHUBOVRRNUUAAA